Document is current
Any future updates will be listed below
-
Authors
Willoughby, Jane E https://orcid.org/0000-0002-6326-4519
Dou, Lang
Bhattacharya, Sabyasachi
Jackson, Heather
Seestaller-Wehr, Laura
Kilian, David
Bover, Laura
Voo, Kui S
Cox, Kerry L
Murray, Tom
John, Mel
Shi, Hong
Bojczuk, Paul
Jing, Junping
Niederer, Heather
Shepherd, Andrew J
Hook, Laura
Hopley, Stephanie
Inzhelevskaya, Tatyana
Penfold, Chris A
Mockridge, C Ian
English, Vikki
Brett, Sara J
Srinivasan, Roopa
Hopson, Christopher
Smothers, James
Hoos, Axel
Paul, Elaine
Martin, Stephen L
Morley, Peter J
Yanamandra, Niranjan
Cragg, Mark S https://orcid.org/0000-0003-2077-089X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02528357 at ClinicalTrials.govDocuments that mention this clinical trial
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review
https://doi.org/10.1136/jitc-2023-008266
T-cell agonists in cancer immunotherapy
https://doi.org/10.1136/jitc-2020-000966
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations
https://doi.org/10.1136/jitc-2023-008677
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
https://doi.org/10.1136/jitc-2022-005301
-
Funding
Funding for this research was provided by:
GSK (N/A)
- License Information
